Receptor protein for human B cell stimulatory factor-2

ABSTRACT

An isolated receptor protein for human B cell stimulatory factor-2, capable of specifically binding to the human B cell stimulatory factor-2; DNA coding for the above-mentioned receptor protein; expression vectors containing the above-mentioned DNA; host organisms transformed with the above-mentioned expression vector; a process for production of the receptor protein comprising culturing the host organisms in a medium to produce the receptor protein and recovering the receptor protein from the culture; and a antibody reacting with the protein.

This application is a divisional of U.S. application Ser. No.08/963,196, filed May 27, 1997, now U.S. Pat. No. 5,990,282, which is acontinuation of U.S. application Ser. No. 08/444,296, filed May 18,1995, now U.S. Pat. No. 5,851,793, which is a divisional of U.S.application Ser. No. 07/907,650, filed Jul. 2, 1992, now U.S. Pat. No.5,480,796, which is a divisional of U.S. application Ser. No.07/298,694, filed Jan. 19, 1989, now U.S. Pat. No. 5,171,840.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to a receptor protein for a human B cellstimulatory factor-2 (hereinafter abbreviated as BSF2 receptor), a DNAsequence coding for the BSF2 receptor, and a process for the productionof the BSF2 receptor using genetic engineering techniques.

2. Description of the Related Art

The B-cell stimulatory factor-2 (BSF2) is believed to be a factor whichdifferentiates B-cells to antibody-producing cells. Recently, a cDNAcoding for BSF2 was isolated, and on the basis of information relatingto the DNA sequence and information relating to the partial amino acidsequence of the purified BSF2, the BSF2 was defined as a proteincomprising 184 amino acid residues accompanied by a signal peptideconsisting of 28 amino acid residues (T. Hirano, K. Yoshida and H.Harada et al, Nature, 324 73-76, 1986).

According to recent findings, the BSF2 is believed to induce B cells toproduce antibodies; to stimulate the growth of hybridoma, plasmacytoma,myeloma and the like, to induce the expression of HLA class I antigens;to induce acute phase proteins on hepatocyte; and induce neuraxons (T.Kishimoto and T. Hirano, Ann. Rev. Immunol. 6. 485, 1985). As seen fromthe above, the BSF2 has various important physiological activities, andis extensively related to cell growth (Hirano et al, Summary of the 17thconference of Japan Immunology Association, pp 91, 1987).

On the other hand, Hirano et al., Proc. Natl. Acad. Sci. U.S.A., Vol 84,pp 228, 1987, reported the possibility that an abnormal production ofBSF2 is an etiology of an immune disorder in such diseases as cardiacmixoma, cervical cancer, myeloma, chronic articular rheumatism,Castleman's syndrome, and the like. Accordingly, an inhibitor of theBSF2 would be promising as a diagnostic, prophylactic or therapeuticagent for the above-mentioned diseases.

T. Taga et al., J. Exp. Med. 196, pp 967, 1987, analyzed a BSF2 receptorwhich is found on a cell membrane and specifically linked to the BSF2,and reported the number there on a cell and the binding constant withBSF2. The BSF2 receptor released from cell surface is promising asdiagnostic, prophylactic and therapeutic agents and the like, andtherefore, there is great interest in the progress of research into theBSF2 receptor.

To enable further progress in the research into the BSF2 receptor andthe development of diagnostic, prophylactic and therapeutic agents, theavailability of a large amount of purified BSF2 receptor is essential,although the receptor can be produced in vivo in only a very smallamount.

For the production of proteins, such as the BSF2 receptor, present in avery small amount in an organism, a genetic engineering technique alsoknown as genetic manipulation is used. In this technique, a DNA sequencecoding for a desired protein is cloned, the cloned DNA sequence isoperatively linked with control DNA sequences such as a promoter, andthe DNA sequence is inserted into a vector to construct an expressionvector, which is then used to transform host cells. The transformant iscultured to produce the desired protein. To use such a geneticengineering procedure to produce a target protein, it is necessary toobtain a DNA sequence coding for the target protein. However, the genecoding for the BSF2 receptor has not yet been cloned.

SUMMARY OF THE INVENTION

Accordingly, the present invention provides a BSF2 receptor protein, aDNA sequence coding for the BSF2 receptor protein, vectors containingthe DNA sequence, host cells transformed with the vector, and a processfor the production of the BSF2 receptor using the transformant.

More specifically, the present invention provides an isolated receptorprotein for human B cell stimulatory factor-2, capable of specificallybinding to the human B cell stimulatory factor-2.

The present invention also provides a DNA coding for the above-mentionedreceptor protein.

The present invention further provides expression vectors containing theabove-mentioned DNA.

The present invention, moreover, provides host organisms transformedwith the above-mentioned expression vector.

In addition, the present invention provides a process for the productionof the receptor protein, comprising culturing the host organisms in amedium to produce the receptor protein and recovering the receptorprotein from the culture.

Further, the present invention provides an antibody specificallyreacting with the receptor protein.

Moreover, the present invention provides a hybridoma producing amonoclonal antibody specifically reacting with the receptor protein.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A to 1C represent graphs of fluorescence intensity versus cellfrequency in an experiment wherein cells are stained with fluorescencevia BSF2-biotin-avidin. In the figures, (A) represents a result obtainedwith cells transfected with a negative vector, (B) represents a resultobtained with cells transfected with a vector containing the presentcDNA, and (C) represents a result obtained by treating theabove-mentioned positively transfected cell with biotinated BSF2 in thepresence of an excess amount of BSF2;

FIG. 2 represents a restriction enzyme cleavage map for a cDNAcontaining a DNA sequence coding for the BSF2 receptor, derived from amonocyte U937 cell line in the Example, wherein a box with oblique linesshows a region from a translation initiation codon ATG to a translationstop codon TAG;

FIGS. 3-A to 3-J represent a nucleotide sequence of DNA containing aregion coding for the BSF2 receptor derived from a monicyte U937 cellline, and an amino acid sequence of the BSF2 receptor presumed from thenucleotide sequence. In the sequence, the single underline partrepresents a hydrophobic region at the N-terminal, and the doubleunderline part represents a hydrophobic region at the C-terminal;

FIG. 4 represents a result of a Northern blotting analysis, wherein thepresence or absence of a hybridigation signal conforms to the presenceor absence of the BSF2 receptor from all lines.

FIG. 5 represents a process for the construction of plasmid pΔBSF2RI.1;

FIG. 6 represents a process for the construction of plasmid pΔBSF2RII.5;

FIGS. 7A to 7C are graphs showing fluorescence intensity versus cellfrequency in an experiment for COP cells transfected with plasmidpBSF2R.236: The meanings of A, B and C are the same as in FIGS. 1A to1C;

FIGS. 8A to 8C are graphs showing fluorescence intensity versus cellfrequency in an experiment for COP cells transfected with plasmidpΔBSF2RI.1: The meanings of A, B and C are the same as in FIGS. 1A to1C;

FIGS. 9A to 9C are graphs showing fluorescence intensity versus cellfrequency in an experiment for COP cells transfected with plasmidpΔBSF2RII.5: The meanings of A, B and C are the same as in FIGS. 1A to1C;

FIGS. 10A and B represent a process for the construction of plasmidphBABSF2R, and structure thereof;

FIG. 11 is a graph showing that a protein produced by plasmid phBABSF2Rspecifically binds to BSF2;

FIG. 12 represents a process for the construction of plasmid pSVL345;

FIG. 13 represents a process for the construction of plasmid pSVL324;

FIG. 14 shows a results of the detection by enzyme immuno assay of asoluble BSF2 receptor protein in a supernatant from a culture of COS-1cells transfected with plasmid pSVL345 or pSVL324;

FIG. 15 is a graph showing a specific binding to BSF2 of products in asupernatant from a culture of COS-1 cells transfected with plasmidpSVL345 or pSVL324;

FIG. 16 is a graph showing a competitive inhibition of cold BSF-2 and¹²⁵I-BSF2 for the binding to product in a supernatant from a culture ofCOS-1 cells transfected with plasmic SVL345 or pSVL324;

FIG. 17 is a graph showing that product in a supernatant from a cultureof COS-1 cells transfected with plasmid pSVL345 or pSVL324 binds to boththe MT18 antibody and BSF2;

FIG. 18 represents an electrophoresis pattern wherein the product in asupernatant from a culture of COS-1 cells transfected with plasmidpSVL345 or pSVL324 and a lysate of BSF2 receptor-producer U266 cells asa control were separated by SDS-PAGE and detected with an MT18 antibody;

FIG. 19 schematically represents structures of the BSF2 receptor proteinand shortened analogues thereof; and

FIGS. 20A and 20B are graphs showing fluorescence intensity versus cellfrequency, showing that the MT18 antibody binds only to cells producingthe BSF2 receptor. Wherein A represents a result for JURKAT cells whichdo not produce the BSF2 receptor, and B represents a result for NJBC8cells which produce the BSF2 receptor.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

BSF2 Receptor

The present invention relates to a human receptor for a B cellstimulatory factor-2 (BSF2 receptor) in an isolated form. The BSF2receptor is a protein which specifically binds to the human B cellstimulatory factor-2, and is originally produced in vivo and is presenton a cell membrane. The BSF2 receptor of the present invention includesany protein with an above-mentioned biological activity. In oneembodiment, the BSF2 receptor protein of the present invention has thefollowing amino acid sequence (I):

(N-terminal) Met Leu Ala Val Gly Cys Ala Leu Leu Ala Ala Leu Leu Ala AlaPro Gly Ala Ala Leu Ala Pro Arg Arg Cys Pro Ala Gln Glu Val Ala Arg GlyVal Leu Thr Ser Leu Pro Gly Asp Ser Val Thr Leu Thr Cys Pro Gly Val GluPro Glu Asp Asn Ala Thr Val His Trp Val Leu Arg Lys Pro Ala Ala Gly SerHis Pro Ser Arg Trp Ala Gly Met Gly Arg Arg Leu Leu Leu Arg Ser Val GlnLeu His Asp Ser Gly Asn Tyr Ser Cys Tyr Arg Ala Gly Arg Pro Ala Gly ThrVal His Leu Leu Val Asp Val Pro Pro Glu Glu Pro Gln Leu Ser Cys Phe ArgLys Ser Pro Leu Ser Asn Val Val Cys Glu Trp Gly Pro Arg Ser Thr Pro SerLeu Thr Thr Lys Ala Val Leu Leu Val Arg Lys Phe Gln Asn Ser Pro Ala GluAsp Phe Gln Glu Pro Cys Gln Tyr Ser Gln Glu Ser Gln Lys Phe Ser Cys GlnLeu Ala Val Pro Glu Gly Asp Ser Ser Phe Tyr Ile Val Ser Met Cys Val AlaSer Ser Val Gly Ser Lys Phe Ser Lys Thr Gln Thr Phe Gln Gly Cys Gly IleLeu Gln Pro Asp Pro Pro Ala Asn Ile Thr Val Thr Ala Val Ala Arg Asn ProArg Trp Leu Ser Val Thr Trp Gln Asp Pro His Ser Trp Asn Ser Ser Phe TyrArg Leu Arg Phe Glu Leu Arg Tyr Arg Ala Glu Arg Ser Lys Thr Phe Thr ThrTrp Met Val Lys Asp Leu Gln His His Cys Val Ile His Asp Ala Trp Ser GlyLeu Arg His Val Val Gln Leu Arg Ala Gln Glu Glu Phe Gly Gln Gly Glu TrpSer Glu Trp Ser Pro Glu Ala Met Gly Thr Pro Trp Thr Glu Ser Arg Ser ProPro Ala Glu Asn Glu Val Ser Thr Pro Met Gln Ala Leu Thr Thr Asn Lys AspAsp Asp Asn Ile Leu Phe Arg Asp Ser Ala Asn Ala Thr Ser Leu Pro Val GlnAsp Ser Ser Ser Val Pro Leu Pro Thr Phe Leu Val Ala Gly Gly Ser Leu AlaPhe Gly Thr Leu Leu Cys Ile Ala Ile Val Leu Arg Phe Lys Lys Thr Trp LysLeu Arg Ala Leu Lys Glu Gly Lys Thr Ser Met His Pro Pro Tyr Ser Leu GlyGln Leu Val Pro Glu Arg Pro Arg Pro Thr Pro Val Leu Val Pro Leu Ile SerPro Pro Val Ser Pro Ser Ser Leu Gly Ser Asp Asn Thr Ser Ser His Asn ArgPro Asp Ala Arg Asp Pro Arg Ser Pro Tyr Asp Ile Ser Asn Thr Asp Tyr PhePhe Pro Arg (C-terminal)

wherein Ala represents L-alanine, Arg represents L-arginine, Asnrepresents L-asparagine, Asp represents L-aspartic acid, Cys representsL-cysteine, Gln represents L-glutamine, Glu represents L-glutamic acid,Gly represents glycine, His represents L-histidine, Ile representsL-isoleucine, Leu represents L-leucine, Lys represents L-lysine, Metrepresents L-methionine, Phe represents L-phenylalanine, Pro representsL-proline, Ser represents L-serine, Thr represents L-threonine, Trprepresents L-tryptophan, Tyr represents L-threosine, Trp representsL-tryptophan, Tyr represents L-tyrosine, and Val represents L-valine.

The amino acid sequence of the present BSF2 receptor protein representedby the sequence (I) consists of 468 amino acid residues, and containstwo hydrophobic regions, i.e., an N-terminal hydrophobic region from thesecond leucine to the 22nd proline, and C-terminal hydrophobic regionfrom the 362nd valine to the 386th leucine. The former is expected to bea signal peptide region and the latter to be a region responsible forthe penetration of the protein through a cell membrane (membranepenetration region). Note, within the present invention, a regionbetween the signal peptide region and the membrane penetration region isdesignated as an “extracellular protein region”, and a region of aC-terminal from the membrane penetration region is designated as an“intracellular protein region”.

The BSF2 receptor of the present invention includes, in addition to theprotein having the above-mentioned particular amino acid sequence, anyproteins or polypeptides capable of specifically binding to the BSF2.For example, modified proteins or polypeptides wherein one or more thanone amino acid residue in the above-mentioned amino acid is replaced bya different amino acid residue; one or more than one amino acid residueis deleted; or one or more than one amino acid residue is added to theabove-mentioned amino acid sequence, while maintaining the biologicalactivity of the native BSF2 receptor. For example, proteins wherein anamino acid sequence and/or an amino acid residue excluding a region inthe above-mentioned amino acid sequence, which relates to binding withthe BSF2, are deleted or replaced with another amino acid sequenceand/or an amino acid residue, and proteins wherein an amino acidsequence and/or an amino acid residue are added to the above-mentionedamino acid sequence at the N-terminal and/or C-terminal thereof.Moreover, the present BSF2 receptor may be a fusion protein wherein anyone of the above-mentioned proteins is fused with another protein suchas a human growth hormone, or a fragment thereof.

For example, the biologically active modified proteins wherein aminoacid residues in the above-mentioned amino acid sequence (I) aredeleted, include proteins wherein amino acid residues near theN-terminal in the amino acid sequence (I) are deleted. An embodiment ofsuch a modified protein has an amino acid sequence wherein an amino acidsequence from the 28th amino acid to the 109th amino acid is deletedfrom the amino acid sequence (I), and represented by the following aminoacid sequence (II):

(N-terminal) Met Leu Ala Val Gly Cys Ala Leu Leu Ala Ala Leu Leu Ala AlaPro Gly Ala Ala Leu Ala Pro Arg Arg Cys Pro Ala Val Asp Val Pro Pro GluGlu Pro Gln Leu Ser Cys Phe Arg Lys Ser Pro Leu Ser Asn Val Val Cys GlyPro Arg Ser Thr Pro Glu Trp Ser Leu Thr Thr Lys Ala Val Leu Leu Val ArgLys Phe Gln Asn Ser Pro Ala Glu Asp Phe Gln Glu Pro Cys Gln Tyr Ser GlnGlu Ser Gln Lys Phe Ser Cys Gln Leu Ala Val Pro Glu Gly Asp Ser Ser PheTyr Ile Val Ser Met Cys Val Ala Ser Ser Val Gly Ser Lys Phe Ser Lys ThrGln Thr Phe Gln Gly Cys Gly Ile Leu Gln Pro Asp Pro Pro Ala Asn Ile ThrVal Thr Ala Val Ala Arg Asn Pro Arg Trp Leu Ser Val Thr Trp Gln Asp ProHis Ser Trp Asn Ser Ser Phe Tyr Arg Leu Arg Phe Glu Leu Arg Tyr Arg AlaGlu Arg Ser Lys Thr Phe Thr Thr Trp Met Val Lys Asp Leu Gln His His CysVal Ile His Asp Ala Trp Ser Gly Leu Arg His Val Val Gln Leu Arg Ala GlnGlu Glu Phe Gly Gln Gly Glu Trp Ser Glu Trp Ser Pro Glu Ala Met Gly ThrPro Trp Thr Glu Ser Arg Ser Pro Pro Ala Glu Asn Glu Val Ser Thr Pro MetGln Ala Leu Thr Thr Asn Lys Asp Asp Asp Asn Ile Leu Phe Arg Asp Ser AlaAsn Ala Thr Ser Leu Pro Val Gln Asp Ser Ser Ser Val Pro Leu Pro Thr PheLeu Val Ala Gly Gly Ser Leu Ala Phe Gly Thr Leu Leu Cys Ile Ala Ile ValLeu Arg Phe Lys Lys Thr Trp Lys Leu Arg Ala Leu Lys Glu Gly Lys Thr SerMet His Pro Pro Tyr Ser Leu Gly Gln Leu Val Pro Glu Arg Pro Arg Pro ThrPro Val Leu Val Pro Leu Ile Ser Pro Pro Val Ser Pro Ser Ser Leu Gly SerAsp Asn Thr Ser Ser His Asn Arg Pro Asp Ala Arg Asp Pro Arg Ser Pro TyrAsp Ile Ser Asn Thr Asp Tyr Phe Phe Pro Arg. (C-terminal)

Further, other types of the biologically active modified proteinswherein amino acid residues in the above-mentioned amino acid sequence(I) are deleted, include proteins wherein amino acid residues of theC-terminal portion in the amino acid sequence (I) are deleted. Anembodiment of such modified protein has an amino acid sequence whereinan amino acid sequence from the 324th amino acid to the 468th amino acidare deleted, and represented by the following amino acid sequence (III):

(N-terminal) Met Leu Ala Val Gly Cys Ala Leu Leu Ala Ala Leu Leu Ala AlaPro Gly Ala Ala Leu Ala Pro Arg Arg Cys Pro Ala Gln Glu Val Ala Arg GlyVal Leu Thr Ser Leu Pro Gly Asp Ser Val Thr Leu Thr Cys Pro Gly Val GluPro Glu Asp Asn Ala Thr Val His Trp Val Leu Arg Lys Pro Ala Ala Gly SerHis Pro Ser Arg Trp Ala Gly Met Gly Arg Arg Leu Leu Leu Arg Ser Val GlnLeu His Asp Ser Gly Asn Tyr Ser Cys Tyr Arg Ala Gly Arg Pro Ala Gly ThrVal His Leu Leu Val Asp Val Pro Pro Glu Glu Pro Gln Leu Ser Cys Phe ArgLys Ser Pro Leu Ser Asn Val Val Cys Glu Trp Gly Pro Arg Ser Thr Pro SerLeu Thr Thr Lys Ala Val Leu Leu Val Arg Lys Phe Gln Asn Ser Pro Ala GluAsp Phe Gln Glu Pro Cys Gln Tyr Ser Gln Glu Ser Gln Lys Phe Ser Cys GlnLeu Ala Val Pro Glu Gly Asp Ser Ser Phe Tyr Ile Val Ser Met Cys Val AlaSer Ser Val Gly Ser Lys Phe Ser Lys Thr Gln Thr Phe Gln Gly Cys Gly IleLeu Gln Pro Asp Pro Pro Ala Asn Ile Thr Val Thr Ala Val Ala Arg Asn ProArg Trp Leu Ser Val Thr Trp Gln Asp Pro His Ser Trp Asn Ser Ser Phe TyrArg Leu Arg Phe Glu Leu Arg Tyr Arg Ala Glu Arg Ser Lys Thr Phe Thr ThrTrp Met Val Lys Asp Leu Gln His His Cys Val Ile His Asp Ala Trp Ser GlyLeu Arg His Val Val Gln Leu Arg Ala Gln Glu Glu Phe Gly Gln Gly Glu TrpSer Glu Trp Ser Pro Glu Ala Met Gly Thr Pro Trp Thr Glu Ser Arg Ser ProPro Val. (C-terminal)

Another embodiment of the modified protein wherein a C-terminal portionof the amino acid sequence (I) is deleted, has the following amino acidsequence (IV):

(N-terminal) Met Leu Ala Val Gly Cys Ala Leu Leu Ala Ala Leu Leu Ala AlaPro Gly Ala Ala Leu Ala Pro Arg Arg Cys Pro Ala Gln Glu Val Ala Arg GlyVal Leu Thr Ser Leu Pro Gly Asp Ser Val Thr Leu Thr Cys Pro Cly Val GluPro Glu Asp Asn Ala Thr Val His Trp Val Leu Arg Lys Pro Ala Ala Gly SerHis Pro Ser Arg Trp Ala Gly Met Gly Arg Arg Leu Leu Leu Arg Ser Val GlnLeu His Asp Ser Gly Asn Tyr Ser Cys Tyr Arg Ala Gly Arg Pro Ala Gly ThrVal His Leu Leu Val Asp Val Pro Pro Glu Glu Pro Gln Leu Ser Cys Phe ArgLys Ser Pro Leu Ser Asn Val Val Cys Glu Trp Gly Pro Arg Ser Thr Pro SerLeu Thr Thr Lys Ala Val Leu Leu Val Arg Lys Phe Gln Asn Ser Pro Ala GluAsp Phe Gln Glu Pro Cys Gln Tyr Ser Gln Glu Ser Gln Lys Phe Ser Cys GlnLeu Ala Val Pro Glu Gly Asp Ser Ser Phe Tyr Ile Val Ser Met Cys Val AlaSer Ser Val Gly Ser Lys Phe Ser Lys Thr Gln Thr Phe Gln Gly Cys Gly IleLeu Gln Pro Asp Pro Pro Ala Asn Ile Thr Val Thr Ala Val Ala Arg Asn ProArg Trp Leu Ser Val Thr Trp Gln Asp Pro His Ser Trp Asn Ser Ser Phe TyrArg Leu Arg Phe Glu Leu Arg Tyr Arg Ala Glu Arg Ser Lys Thr Phe Thr ThrTrp Met Val Lys Asp Leu Gln His His Cys Val Ile His Asp Ala Trp Ser GlyLeu Arg His Val Val Gln Leu Arg Ala Gln Glu Glu Phe Gly Gln Gly Glu TrpSer Glu Trp Ser Pro Glu Ala Met Gly Thr Pro Trp Thr Glu Ser Arg Ser ProPro Ala Glu Asn Glu Val Ser Thr Pro Met Gln Ala Ler Thr Thr Asn Lys AspAsp Asp Asn Ile Leu. (C-terminal)

DNA Sequence Coding for BSF2 Receptor

DNA sequences of the present invention include those coding for any oneof the above-mentioned BSF2 receptor proteins.

In an embodiment, the present DNA sequences are those coding for theamino acid sequence represented by the sequence (I). Due to thedegeneracy of codons, there may be many particular DNA sequences. TheDNA sequence of the present invention can be prepared by anyconventional procedure. For example, a nucleotide sequence of thepresent DNA can be designed according to the above-mentioned amino acidsequence, considering codons frequently used in a host cell which ischosen for the production of the BSF2 receptor protein and can bechemically synthesized. Alternatively, the desired DNA may be preparedfrom a genome of BSF2 receptor producing cells.

Most conveniently, however, a DNA fragment containing gene coding forthe BSF2 receptor can be prepared as cDNA from the BSF2 receptorproducing cells, such as the NK cell YT, monocyte cell line U937,myeloma cell line U266, B cell CESS. Namely, mRNA is extracted fromcultured cells of any of the above-mentioned cells lines according to aconventional procedure, and a cDNA library is constructed on the basisof the mRNA.

The cDNA library may be then screened using an oligonucleotide probecorresponding to a part of the above-mentioned sequence (II).Alternatively, and preferably, according to the present invention, thecDNA library can be screened without a probe. In this procedure, thecDNA library is used to prepare vectors containing cDNA, which are thenused to transform animal cells. The cells are then cultured, and thecultured cells are treated with a biotinated BSF2 preparation. Duringthis procedure, cells which have expressed the BSF2 receptor bind theBSF2 moiety of the biotinated BSF2. The treated cells are then treatedwith avidin conjugated with fluorescein isocyanate to react the biotinmoiety fixed to the cells with the avidin moiety of theavidin-fluorescein isocyanate conjugate. Subsequently, cells which haveexpressed the BSF2 receptor, and therefore carry fluorescein isocyanateon their surface, are separated and selected by a cell sorter. Thedesired cDNA coding for the BSF2 receptor is then extracted from theselected cells. An embodiment of a cDNA thus obtained has the followingsequence (V):

(5′-terminal) ATG CTG GCC GTC GGC TGC GCG CTG CTG GCT GCC CTG CTG GCCGCG CCG GGA GCG GCG CTG GCC CCA AGG CGC TGC CCT GCG CAG GAG GTG GCA AGAGGC GTG CTG ACC AGT CTG CCA GGA GAC AGC GTG ACT CTG ACC TGC CCG GGG GTAGAG CCG GAA GAC AAT GCC ACT GTT CAC TGG GTG CTC AGG AAG CCG GCT GCA GGCTCC CAC CCC AGC AGA TGG GCT GGC ATG GGA AGG AGG CTG CTG CTG AGG TCG GTGCAG CTC CAC GAC TCT GGA AAC TAT TCA TGC TAC CGG GCC GGC CGC CCA GCT GGGACT GTG CAC TTG CTG GTG GAT GTT CCC CCC GAG GAG CCC CAG CTC TCC TGC TTCCGG AAG AGC CCC CTC AGC AAT GTT GTT TGT GAG TGG GGT CCT CGG AGC ACC CCATCC CTG ACG ACA AAG GCT GTG CTC TTG GTG AGG AAG TTT CAG AAC AGT CCG GCCGAA GAC TTC CAG GAG CCG TGC CAG TAT TCC CAG GAG TCC CAG AAG TTC TCC TGCCAG TTA GCA GTC CCG GAG GGA GAC AGC TCT TTC TAC ATA GTG TCC ATG TGC GTCGCC AGT AGT GTC GGG AGC AAG TTC AGC AAA ACT CAA ACC TTT CAG GGT TGT GGAATC TTG CAG CCT GAT CCG CCT GCC AAC ATC ACA GTC ACT GCC GTG GCC AGA AACCCC CGC TGG CTC AGT GTC ACC TGG CAA GAC CCC CAC TCC TGG AAC TCA TCT TTCTAC AGA CTA CGG TTT GAG CTC AGA TAT CGG GCT GAA CGG TCA AAG ACA TTC ACAACA TGG ATG GTC AAG GAC CTC CAG CAT CAC TGT GTC ATC CAC GAC GCC TGG AGCGGC CTG AGG CAC GTG GTG CAG CTT CGT GCC CAG GAG GAG TTC GGG CAA GGC GAGTGG AGC GAG TGG AGC CCG GAG GCC ATG GGC ACG CCT TGG ACA GAA TCC AGG AGTCCT CCA GCT GAG AAC GAG GTG TCC ACC CCC ATG CAG GCA CTT ACT ACT AAT AAAGAC GAT GAT AAT ATT CTC TTC AGA GAT TCT GCA AAT GCG ACA AGC CTC CCA GTGCAA GAT TCT TCT TCA GTA CCA CTG CCC ACA TTC CTG GTT GCT GGA GGG AGC CTGGCC TTC GGA ACG CTC CTC TGC ATT GCC ATT GTT CTG AGG TTC AAG AAG ACG TGGAAG CTG CGG GCT CTG AAG GAA GGC AAG ACA AGC ATG CAT CCG CCG TAC TCT TTGGGG CAG CTG GTC CCG GAG AGG CCT CGA CCC ACC CCA GTC CTT GTT CCT CTC ATCTCC CCA CCG GTG TCC CCC AGC AGC CTG GGG TCT GAC AAT ACC TCG AGC CAC AACCGA CCA GAT GCC AGG GAC CCA CGG AGC CCT TAT GAC ATC AGC AAT ACA GAC TACTTC TTC CCC AGA. (3′-terminal)

The DNA sequence of the present invention includes, in addition to theabove-mentioned sequence (V), those wherein one or more than onenucleotide in the above-mentioned sequence (V) is replaced by othernucleotides, or wherein one or more than one codon is added to ordeleted from the sequence (V), still coding for a protein capable ofbinding to the BSF2.

For example, a DNA coding for a shortened or truncated BSF2 receptorprotein can be prepared by cleaving the above-mentioned cDNA having thenucleotide sequence (V) with an appropriate restriction enzyme to deletea portion of the nucleotide sequence and re-ligating the cleaved DNAfragments if necessary via an appropriate linker.

For example, a vector containing the cDNA having the nucleotide sequence(V) can be manipulated according to Example 6, to prepare a vectorcontaining a DNA coding for a protein consisting of an amino acidsequence 1 to 123 and an amino acid sequence 343 to 468 of theabove-mentioned amino acid sequence (I). Similarly, a vector containinga DNA coding for a protein consisting of an amino acid sequence 1 to 27and amino acid sequence 110 to 468 of the amino acid sequence (I) can beprepared.

In another embodiments any nucleotide in the above-mentioned vector canbe deleted or replaced by another nucleotide by site-specificinvitro-mutagenesis. In this manner, a translation stop codon can beintroduced at any position of the cDNA coding for BSF2 receptor proteinto obtain a DNA coding for any C-terminal truncated BSF2 receptorprotein. For example, as shown in Example 11, a vector containing a DNAcoding for a protein having an amino acid sequence 1 to 344 of the aminoacid sequence (I) is constructed. According to a similar procedure, avector containing DNA coding for a protein having an amino acid sequence1 to 323 of the amino acid sequence (I) is constructed.

Next, the DNA, for example, cDNA, coding for the BSF2 receptor is linkedwith DNA sequences necessary for the expression of the BSF2 receptor ina host. Such DNA sequences include a promoter, start codon and stopcodon of the transcription and translation, and are selected dependingon the nature of the host used. Among the DNA sequences necessary forthe expression, the promoter is important. A promoter which can be usedas a bacterial host includes known promoters such as β-lactamase andlactose promoter, tryptophan promoter, and hybrid promoters derivedtherefrom. For a yeast host, for example, GAL4 promoter can be used.

In addition to the above-mentioned DNA sequences necessary for theexpression of the BSF2 receptor, preferably another control sequencesuch as a ribosome binding site is linked with the DNA coding for theBSF2 receptor.

The DNA sequence coding for the BSF2 receptor is linked with theabove-mentioned DNA sequences necessary for the expression of the BSF2receptor in a manner such that the DNA sequence coding for BSF2 receptorcan be transcribed and transformed in a selected host under the controlof the DNA sequences necessary for the expression of the BSF2. Thelinkage is usually carried out by ligation via cohesive ends or bluntends, preferably via cohesive ends, of the DNA sequences to be linked.

According to a preferable embodiment of the present invention, the BSF2receptor protein is expressed as a fusion protein with a partnerprotein, such as a human growth hormone protein. In such a case, the5′-end of the DNA sequence coding for the BSF2 receptor is ligated in areading frame with the 3′-end of a DNA sequence coding for the partnerprotein, such as the human growth hormone protein.

Expression Vector

Expression vectors of the present invention contain, in addition to theabove-mentioned DNA sequence coding for the BSF2 receptor linked withthe DNA sequences necessary for the expression of the BSF2 receptor, anorigin of replication and at least one selective maker gene. Thesecomponents of the expression vector are selected in accordance with thehost organism used. For example, when a bacterium such as E. coli isused as a host, an origin of replication is derived from conventional E.coli plasmids such as pBR322, pBR337 or the like. For a yeast host, theorigin of replication is preferably Cal4 or α-Factor. Where animal cellssuch as mammalian cells are used as host cells, the origin ofreplication is preferably derived from a virus such as the SV40 virus.

The choice of selective maker gene also depends on the host organisms.Selective maker genes useful for bacterial hosts are, for example,ampicillin resistant gene, tetracycline resistant gene, or the like.

Host Organism

In the present invention, any conventional host organisms includingmicroorganisms, and animal cells can be used. As the bacterial hosts,various strains of E. coli such as K-12, x-1776, w-3110, MC 1009 and thelike are typically used. Moreover, Bacillus such as Bacillus subtilis,Salmonella typhimurium, Serratia marcescens, Pseudomonas, and certainthermophilic bacteria can be used. As the yeast host, for example,Saccharomyces, such as Saccharomyces cerevisiae can be used, and as themammalian host, cell lines such as COS cells derived from the renalfibroblast of a monkey, CHO cells (Chinese hamster ovary cells), WI38,BHK, 3T3, VERO, HeLa, etc., can be used.

Production of BSF2 Receptor Using Transformant

The BSF2 receptor is produced by culturing transformant cells preparedby transforming the above-mentioned host with the above-mentionedexpression vector to express the BSF2 receptor, and recovering the BSF2receptor from the culture. The expression is induced by de-repression oractivation of the promoter in the expression vector. Usually, thetransformant cells are grown to a predetermined density under thecondition wherein the promoter is repressed, after that the promoter isde-repressed or activated to express the BSF2 receptor. For thispurpose, for example, indole acetic acid (IAA) for trp promoter,isopropyl-β-D-thio-galactopyranoside (IPTG) for tac promoter is used.

Antibodies to the BSF2 Receptor

The present invention also provides antibodies to the BSF2 receptor. Thepresent antibodies include any antibodies specifically bound to the BSF2receptor produced by any of the above-mentioned BSF2 receptor producingcell lines, or to any of the above-mentioned recombinant BSF2 receptors.The antibodies may be polyclonal or monoclonal and may be produced byhuman, mouse, rabbit, sheep or goat, or by hybridoma derived from thereanimals. As antigens used to immunize animals to produce polyclonalantibodies, or to prepare hybridoma for the production of monoclonalantibodies, cells expressing the BSF2 receptor, BSF2 receptor proteinsproduced by the above-mentioned cell lines, and various recombinant BSF2receptor proteins can be used.

The present polyclonal and monoclonal antibodies can be producedaccording to a procedure known per se.

According to the present invention, the DNA sequence coding for the BSF2receptor protein, expression vectors containing the DNA sequence, andthe transformant containing the DNA sequence are provided. By using thetransformant, a large amount of the BSF2 receptor protein can beproduced, which provides an opportunity to develop prophilactic andtherapeutic pharmaceuticals as well as diagnostic agents relating todeseases or disorders associated with an abnormal production of theBSF2. Moreover, the availability of the BSF2 receptor protein in apurified form will accelerate the studies of an immune mechanism withwhich the BSF2 or BSF2 receptor is concerned.

Moreover, the DNA sequence per se. may be useful as a probe forscreening related genes.

EXAMPLES

The present invention will now be further illustrated by but is by nomeans limited to the following examples.

Example 1 Confirmation of Presence of BSF2 Receptor on Some Cell Lines

The BSF2 receptor specifically binds to BSF2 (T. Taga et al., J. Exp.Med., 166, pp 967, 1987). By using this property, the NK cell YT,monocyte U937 cell line, myeloma U266 cell line, T-cell Jurkat cellline, B-cell CESS cell line, and B-cell BL29 cell line are tested forpossession of the BSF2 receptor.

Cells of each of these cell lines were cultured in Dulbecco's ModifiedEagle's Medium (D-MEM; Dulbeccos) supplemented with 10% fetal calf serum(FCS) according to a conventional procedure. The BSF2 was preparedaccording to a process described in Nature 324 (6) pp 73-76, 1986. Note,the BSF2 can be also prepared according to a process disclosed inJapanese Unexamined Patent Publication No. 61-24697.

Next, the BSF2 thus prepared was labeled with ¹²⁵I according to aprocedure described by T. Taga et al., J. Exp. Med., 166, 967, 1987. The¹²⁵I-labeled BSF2 was reacted with the above-mentioned cultured cellsaccording to a method of Taga et al., supra. After the ¹²⁵I-labeled BSF2non-specifically associated with the cells was washed away, the ¹²⁵Iwhich specifically binds to the BSF₂ producing cells was detected by ascintillation counter. As a result, the presence of the BSF2 receptorwas determined on cells of all of the cell lines tested, except for theB-cell BL29 cell line and T-cell Jurkat cell line.

Example 2 Isolation of mRNA

The isolation of mRNA was carried out according to Manistis et al.,Molecular Cloning, Cold Spring Harbor Laboratory, 1982.

Monocyte U937 (ATCC-CRL-1593) was cultured by the same procedure asdescribed in Example 1, and the cultured cells were washed withphysiological saline. The washed cells were suspended in a solution of50% guanidineisothiocyanate, and the solution was subjected to cesiumchloride density-gradient centrifugation using 5.7M cesium chloride and2.7M cesium chloride at 32000 rpm for 20 hours to obtain a mixture ofm-RNA. The mRNA was suspended in a sodium lauroyl sarcosinate solution,and purified by phenol extraction and ethanol precipitation.

Example 3 Construction of cDNA Library

The mRNA fraction thus obtained was used as a temperate for a synthesisof cDNA. The synthesis was carried out using a cDNA synthesis kit(Applied Biosystems) to obtain a cDNA library.

Example 4 Cloning of Desired cDNA Clone

As a host, COS cells (COS-7 cells) were used; and as a vector compatibleto the COS cells, a CDM8 vector described by Brian Seed, Nature 329, pp840, 1987 was used. The CDMS vector contains a cytomegalovirus promoterand an origin of replication from the SV40 virus, as well as arestriction enzyme cleavage site downstream of the cytomegaloviruspromoter.

Excised cDNA's were ligated to the CDM8 vector which had been digestedwith a restriction enzyme Bst X 1, and the resulting vectors containinga cDNA insert were used to transfect COS cells. Namely, COS cells werecultured in D-MEM supplemented with 10% FCS and transfection was carriedout according to a DEAE-dextran method, and the transfected COS cellswere further cultured for two days. To the cultured COS cells was addeda staining buffer (RPMI 1640 containing 2% FCS, 0.1% NaN₃) supplementedwith biotinated BSF2, and the mixture was incubated at 37° C. for twohours to allow binding of the BSF2 moiety of the biolinated BSF2 withthe BSF2 receptor expressed on the cultured COS cells. The treated cellswere then washed twice with the staining buffer (without the biotinatedBSF2), and to the washed cells was added avidin conjugated withfluorescein isocyanate (FITC) to allow binding of the avidin moiety ofthe avidin-FITC conjugate with the biotin moiety fixed to the cell. Thetreated cells were then washed three times with the staining buffer.

After dead cells were eliminated by adding propidium iodide (PI),fluorescence-labeled COS cells were detected and isolated using aFluorescein Activated Cell Sorter FACS; Becton Dickinson).

For comparison, the COS cells transfected with a vector not containingcDNA were treated according to the same procedure as described above.

Moreover the COS cells transfected with a cDNA-containing vector weretreated with the biotinated BSF2 in the presence of an excess amount offree BSF2 to allow competition between the biotinated BSF2 and the freeBSF2 for binding to BSF2 receptor expressed on the COS cells. After thebiotinated BSF2-treated COS cells were treated with the FITC-avidinaccording to the same procedure as described above, the cells wereanalyzed by the FACS, and the results were as set forth in FIG. 1,wherein the abscissa axis represents the fluorescence intensity, and theordinates axis represents the frequency of the number of cells carryingdifferent fluorescence-intensities. In the Figure, A represents a resultobtained from cells transfected with a vector not containing cDNA, Brepresents a result obtained from cells transfected with vectorscontaining a cDNA according to the present invention, and C represents aresult obtained from cells transfected with vectors containing BSF2receptor cDNA, but treated with the biotinated BSF2 in the presence of aexcess amount of free BSF2.

The graph B shows the presence of cells having high fluorescenceintensity, revealing that a population of cells transfected with vectorscontaining cDNA prepared according to the present invention contains asignificant ratio of cells which produce a substance capable of bindingto the BSF2. On the other hand, as seen from graph C, a population ofcells treated with the biotinated BSF2 under a competitive conditionwith an excess amount of free BSF2 does not contain cells having a highfluorescence intensity, revealing that the binding of the biotinatedBSF2 with the COS cells is BSF2-specific.

From the cells having a high fluorescence intensity, vectors wereextracted and were used to transform E. coli MC1009 (ATCC 33760), andthe trans-formants were cultured to amplify vectors containing a cDNAinsert coding for the BSF2 receptor.

One vector thereamong was then chosen for further experiments anddesignated as pBSF2R.236.

The plasmid pBSF2R.236 partially digested with XhoI to obtain a DNAfragment containing a nucleotide sequence coding for an entire BSF2receptor protein, and the DNA fragment was inserted to the Sal I site ofplasmid pIBI76 (commercially available from IBI) to consturct plasmidpIBIBSF2R. Escherichia coli containing the plasmid pIBIBSF2R wasdeposited with the Fermentation Research Institute Agency of IndustrialScience and Technology, 1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken,Japan, under the Budapest treaty, on Jan. 9, 1989, as FERM BP-2232.

The plasmid pIBISF2R can be cleaved with a suitable restrictionenzyme(s) by a conventional procedure to obtain a DNA fragmentcontaining a nucleotide sequence coding for a BSF2 receptor protein, andthe DNA fragment can be used to construct further plasmids.

Example 5 Analysis of cDNA

The vector DNA pBSF2R.236 prepared in Example 4 was digested with arestriction enzyme to excise the cDNA insert coding for the BSF2, andthe determination of a restriction enzyme cleavage map and nucleotidesequence was carried out according to the M13 method of, J. Messing,Methods in Enzymol. vol. 101, pp 20, 1983.

The results are set forth in FIGS. 2 and 3-1 to 3-5. The DNA coding forthe BSF2 receptor consists of 1404 base pairs flanked by a translationstart codon ATG at the 5′-terminal and a translation stop codon TAG atthe 3′-terminal.

Example 6 Confirmation of cDNA coding for BSF2 Receptor

To confirm that the cloned cDNA codes for the target BSF2 receptorprotein, the above-mentioned cell lines, i.e., NK cell line YT, monocytecell line U937, myeloma cell line U266, T-cell Jurkat, B-cell CESS, andB-cell BL29, were cultured and mRNA was extracted from each culture andpurified according to the same procedure as described in Example 2.

The purified mRNA was concentrated by oligo-dT resin (Boehringer), and 1μg of the concentrated mRNA was subjected to 0.8% agarose gelelectrophoresis and transferred to a nitrocellulose filter by Northernblotting.

On the other hand, the vector DNA prepared in Example 4 was digestedwith a restriction enzyme XhoI to excise the DNA fragment coding for theBSF2 receptor, which was then nick-translated to prepare a probe.

For hybridization, the above-mentioned Northern-blotted nitrocellulosesheet was placed in contact with a hybridization buffer comprising 50%formaldehyde, 5×Denhart (1×Denhart=0.02 g/100 ml Ficoll polyvinylpyrrolidone and 0.02 g/ml bovine serum albumin), 5×SSC (1×SSC=8.77 g/lNaCl and 4.41 g/l sodium citrate, pH 7.0), and 10 μg/ml salmon sperm DNAsupplemented with 1×10⁷ cpm/ml of the above-mentioned probe, at 42° C.for 24 hours.

After the hybridization, the nitrocellulose sheet was washed twice in1/10 SSC at 50° C. for 20 minutes each to eliminate the probenon-specifically associated with the nitrocellulose sheet, and thendried. The sheet was exposed to an x-ray film for autoradiography, andthe results were as set forth in FIG. 4.

As seen from the Figure, mRNA's extracted from monocyte cell line U937,myeloma cell line U266, B-cell line CESS, and NK cell line YT, whichwere previously confirmed as expressing the BSF2 receptor in Example 1,hybridized with the cloned cDNA. On the other hand, mRNA's extractedfrom the B-cell line BL29 and T-cell line Jurkat, which were previouslyconfirmed as not expressing the BSF2 receptor, did not hybridize withthe cloned DNA. This result supports the fact that the cloned cDNA ofthe present invention actually codes for the BSF-2 receptor protein.

Note, T. Taga, supra, disclosed the number of BSF2 receptor per cell forsome cell lines, as follows:

Cell line Number of cells on cell membrane U937 3 × 10³/cell U266 2 ×10⁴/cell CESS 3 × 10³/cell BL29 negative Jurkat negative YT 5 × 10³/cell

The T. Taga et al. result also supports the above-mentioned conclusion.

FIG. 3 represents, in addition to the DNA sequence of the presentinvention, a presumed amino acid sequence of the present BSF2 receptorconsisting of 468 amino acid residues whose N-terminal amino acid ismethionine corresponding to the translation start codon. The amino acidsequence contained two hydrophobic regions, one of which was positionedat the N-terminal side and was considered to be a signal peptide, andanother of which was positioned on the C-terminal side and wasconsidered to be a region responsible for the penetration of the proteinthrough the cell membrane. This supports the assumption that the BSF-2receptor penetrates the cell membrane and reaches the inside of thecell.

Example 6 Construction of Plasmid pΔBSF2RI.1 (FIG. 5)

To prepare a plasmid containing a DNA coding for a modified BSF2receptor protein wherein a central portion of the native protein isdeleted, the plasmid pBSF2R.236 prepared in Example 4 and containing acDNA coding for an entire BSP2 receptor protein was used.

The plasmid pBSF2R.236 was cleaved with Hind III and MroI, and agenerated DNA fragment was blunt-ended with a Klenow fragment of DNApolymerase, and cleaved with XhoI to obtain a DNA fragment A. Further,pBSF2R.236 was cleaved with SspI and PstI to obtain an 800 bp DNAfragment B. Still further, a CDM8 vector was cleaved with XhoI and PstI,and treated with BAP to obtain a vector fragment C. The above-mentionedfragments A, B and C were then ligated using a ligase, and the ligationmixtures were used to transform E. coli MC1061/P3, and a colonyresistant to 125 μg/ml ampicillin and 75 μg/ml tetracycline was selectedas a desired clone, from which a plasmid was obtained, and designatedpΔBSF2RI.1.

This plasmid contains a DNA coding for a protein consisting of aminoacids 1 to 123 and 343 to 468 in the amino acid sequence (I), andlacking a DNA portion coding for amino acids 124 to 342.

Example 7 Construction of Plasmid pΔBSF2RII.5 (FIG. 6)

To prepare a plasmid containing a DNA coding for a modified BSF2 vectorprotein, wherein a portion near the N-terminal of the native BSF2receptor protein was deleted, the plasmid pBSF2R.236, prepared inExample 4, containing a cDNA coding for an entire BSF2 receptor protein,was used.

The plasmid pBSF2R.236 was cleaved with XhoI and FspI to isolate a 450bp DNA fragment D. Further, pBSF2R.236 was cleaved with ApaLI and XbaIto isolate a 1.5 kbp DNA fragment, which was then treated with Mung beannuclease, and cleaved with PstI to obtain a DNA fragment E. Moreover, aCDM8 vector was cleaved with XhoI and PstI, and treated with BAP toobtain a vector DNA fragment F. Next, the above-prepared DNA fragmentsD, E, and F were ligated using DNA ligase. The ligation mixture was usedto transform E. coli MC1061/P3, and a colony resistant to 125 μg/mlampicillin and 75 μg/ml tetraagcline was selected to obtain a desiredclone, from which a plasmid was obtained and designated pΔBSF2RII.5.

This plasmid contained a DNA coding for protein consisting of aminoacids 1 to 27 and 110 to 468 of the amino acid sequence (I), and lackinga DNA portion coding for amino acids 28 to 109.

Example 8 Confirmation of Expressions of BSF2 Receptor Protein

Plasmid pBSF2R.236 constructed in Example 4, plasmid pΔBSF2RI.1constructed in Example 6, and plasmid pΔBSF2RII.5 constructed in Example7 were separately transfected to mouse COP cells (C. Tyndall et al.,Nucleic Acid Res., 9, 6231, 1981) by the DEAE-dextran method (Secd, B.and Aruffo, A., PNAS, 84: 3365), and the cells were cultured in a DMEMmedium containing 20% fetal calf serum (FCS). Using the same procedureas described in Example 1, it was determined whether the cultured cellsexpressed a desired protein, in a cell sorter using fluorescencestaining (FACS440). The results are shown in FIG. 7 (for pBSF2R.236),FIG. 8 (for pΔBSF2RI.1), and FIG. 9 (for pΔBSF2RII.5). As seen fromthese Figures, although COP cells transfected with pBSF2R.236 (FIG. 7B)and COP cells transfected with pBSF2RII.5 (FIG. 9B) were stained, COPcells transfected with pΔBSF2RI.1 (FIG. 8B) were not stained. Thestaining was prevented by the addition of an excess amount ofrecombinant BSI2 (FIG. 7C and FIG. 9C). As a result, it was confirmedthat both the pBSF2R.236 and pBSF2II.5 provide a protein having a BSF2receptor activity, revealing that a protein wherein a protein of theamino acid sequence near the N-terminal of the native BSF2 receptorprotein has been deleted, exhibits a BSF2 receptor activity.

Example 9 Production of Soluble BSF2 Receptor Protein (1) (FIGS. 10 and11)

To produce a soluble BSF2 receptor protein, a protein wherein a portionexpected to be a membrane penetration region and a portion expected tobe an intracellular protein region present at a C-terminal of the BSF2receptor protein were deleted, was prepared. To this end, an expressionplasmid phβABSF2R was constructed which comprised a vector portion basedon plasmid PUC9; a BSF2 receptor expression unit comprising a human βactin promoter (S. Nakajima et al., Proc. Natl. Acad. Sci. USA, 82,6133, 1985), a soluble BSF2 receptor cDNA, and a translation stop codonlinked in this order.

Namely, the plasmid pBSF2R.236 was cleaved with Sphl to obtain a cDNAfragment containing codons for a first amino acid to a 402th amino acidof the native BSF2 receptor. This fragment was inserted to a phagevector M13 mp18 at the SphI site thereof, and site specific in-vitromutagenesis was carried out using an oligonucleotide primer5′-ATATTCTCTAGAGAGATTCT-3′ and a site specific in-vitro mutagenesissystem (Amersham) to prepare a mutant phase M13 mp18 (345) wherein a TAGtermination codon had been inserted immediately after the 344th aminoacid codon. This mutant phage in a replicating form was cleaved withHind III and SalI to obtain a DNA fragment (A) coding for an N-terminalside of the BSF2 receptor protein wherein a 345th amino acid codon hadbeen replaced by a translation termination codon TAG. Moreover, aplasmid pECE (L. Ellis et al., Cell, 45, 721, 1986) containing β-globinpoly A was cleaved with SalI and BamHI to obtain a DNA fragment (B)containing β-globin poly A. Further, a plasmid comprising a human βactin promoter inserted in a plasmid PUC9 was cleaved with HindII andBamHI to obtain a linear plasmid (C) comprising a human β actin promoterand PUC9 vector. Next, these DNA fragments were ligated using DNA ligaseto construct an expression plasmid phβABSF2R. A process for theconstruction of this plasmid and the structure thereof are shown in FIG.10.

Soluble BSF2 receptor protein was prepared using the plasmid phβABSF2R,as follows. To mouse fibroblast cells (L cells, ATCC CCL1) cultured in aDMEM medium by a conventional procedure was added 20 μg/petri dish ofphβABSF2R using a calcium phosphate method kit (Pharmacia). The mediumwas replaced the next day, and after a further culturing for two days, aculture supernatant was recovered. Detection of the soluble BSF2receptor protein in the supernatant was carried out using an MT18antibody prepared by the procedure described in Example 11 and ¹²⁵I-BSF2prepared by the procedure described in Example 1. Namely, 100 μl each ofPBS containing 1 μg/ml of an MT18 antibody was put into each well of a96-well microtiter plate, and the plate was incubated at 4° C.overnight. After washing, 100 μl/well of 1% BSA was added, and the platewas incubated for two hours at room temperature. After washing, 100μl/well of the above-mentioned culture supernatant from the L medium wasadded, and the plate was incubated at a room temperature for two hours,and then washed. Next, 100 μl/well of ¹²⁵I-BSF2, corresponding to 20,000cpm/well, was added to the well, and the plate was incubated at roomtemperature for two hours, and then washed. The plate was cut toseparate each well, and bound radioactivity was measured by a γ-counter.Further, to confirm the specificity of the product, the above-mentionedprocedure was carried out using the supernatant supplemented with 200ng/ml of non-labeled BSF2 instead of the supernatant alone.

For comparison, DMEM containing 10% FCS but not inoculated with cells,and a culture supernatant of L cells not transfected with plasmid weretreated by the same procedure described above, and bound radioactivitywas measured by a γ-counter.

The results are shown in FIG. 11. As seen from this Figure, in contrastwith the DMEM medium containing 10% FCS and a culture supernatant of Lcells not transfected with plasmid, a culture supernatant of L cellstransfected with phβABSF2R contained a substance which binds to both theTM18 antibody and ¹²⁵I-BSF2. Further, where a culture supernatant of Lcells transfected with phβABSF2R and supplemented with 200 ng/mlnon-labeled BSF2 was added instead of the supernatant alone, the boundradioactivity was significantly reduced. This shows that the product isa soluble BSF2 receptor.

Example 10 Production of Soluble BSF2 Receptor Protein (2) (FIGS. 12 to18)

Construction of Plasmid pSVL345

To produce a soluble BSF2 receptor protein in COS-1 cells, proteinwherein a portion expected to be a membrane penetration region and aportion expected to be an intracellular protein region present at aC-terminal of the BSF2 receptor protein were deleted, was prepared. Tothis end, an expression plasmid pSVL345 was constructed which compriseda vector portion based on plasmid pSVL (Pharmacia); a BSF2 receptorexpression unit comprising an SV40 late promoter contained in pSVL, asoluble BSF2 receptor cDNA, and a translation stop codon linked in thisorder; and SV40 polyadenylation signal.

Namely, the plasmid pBSF2R.236 was cleaved with Sphl to obtain a cDNAfragment containing codons for a first amino acid to a 402th amino acidof the native BSF2 receptor. This fragment was inserted to a phagevector M13 mp18 at the SphI site thereof, and site specific in-vitromutagenesis was carried out using an oligonucleotide primer5′-ATATTCTCTAGAGAGATTCT-3′ and a site specific in-vitro mutagenesissystem (Amersham) to prepare a mutant phage M13 mp18 (345) wherein a TAGtermination codon had been inserted in place of the 345th amino acidcodon. This mutant phage in a replicating form was cleaved with Hind IIIand SalI to obtain a DNA fragment coding for an N-terminal side of theBSF2 receptor protein wherein a 345th amino acid codon had been replacedby a translation termination codon TAG.

This DNA fragment was inserted in the SphI site of a plasmid pSP73(available from Promegabiotch) to construct a plasmid wherein the DNAfragment has been inserted so that the XhoI site is present near to the5′-side of BSF2 receptor and the BamHI site is present near to the3′-side of the BSF2 receptor gene. This plasmid was cleaved with XhoIand BamHI to obtain a DNA fragment (A) containing a nucleotide sequencecoding for 344 amino acids of the N-terminal side of a BSF2 receptor. Onthe other hand, the basic plasmid pSVL was cleaved with XhoI and BamHI,and treated with alkaline phosphatase to obtain a linearized plasmidDNA. Next, this linearized DNA and the DNA fragment (A) were ligatedwith T4 DNA ligase to construct an expression plasmid pSVL345. A processfor the construction of this plasmid is set forth in FIG. 12.

Construction of Plasmid pSVL324

To produce a soluble BSF2 receptor protein, a protein wherein a portionexpected to be a membrane penetration region and a portion expected tobe an intracellular protein region present at a C-terminal of the BSF2receptor protein were deleted, was prepared. To this end, an expressionplasmid pSVL345 was constructed which comprised a vector portion basedon plasmid pSVL (pharmacia); a BSF2 receptor expression unit comprisingan SV40 late promoter contained in pSVL, a soluble BSF2 receptor cDNA,and a translation stop codon linked in this order; and SV40polyadenylation signal.

Namely, the plasmid pBSF2R.236 was cleaved with Sphl to obtain a cDNAfragment containing codons for a first amino acid to a 402th amino acidof the native BSF2 receptor. This fragment was inserted to a phagevector M13 mp18 at the SphI site thereof, and site specific in-vitromutagenesis was carried out using an oligonucleotide primer5′-GTCCTCCAGTCTAGAACGAGGT-3′ and a site specific in-vitro mutagenesissystem (Amersham) to prepare a mutant phage M13 mp18 (324) wherein a TAGtermination codon had been inserted in place of the 324 amino acidcodon. This mutant phage in a replicating form was cleaved with SphI toobtain a DNA fragment coding for an N-terminal side of the BSF2 receptorprotein wherein a codon for 323th alanine has been changed to a codonfor valine and a 324th amino acid codon had been replaced by atranslation termination codon TAG.

This DNA fragment was inserted in the SphI site of a plasmid pSP73(available from Promegabiotch) to construct a plasmid wherein the DNAfragment has been inserted so that the XhoI site is present near to the5′-side of BSF2 receptor and the BamHI site is present near to the3′-side of BSF2 receptor gene. This plasmid was cleaved with XhoI andBamHI to obtain a DNA fragment (B) containing a nucleotide sequencecoding for 323 amino acids of the N-terminal side of a BSF2 receptor. Onthe other hand, the basic plasmid pSVL was cleaved with XhoI and BamHI,and treated with alkaline phosphatase to obtain a linearized plasmidDNA. Next, this linearized DNA nd the DNA fragment (B) were ligated withT4 DNA ligase to construct an expression plasmid pSVL324. A process forthe construction of this plasmid is set forth in FIG. 13.

Expression of Soluble BSF2 Receptor Protein

An expression or a soluble BSF2 receptor protein using theabove-mentioned plasmids pSVL345 and pSVL324 was carried out as follow.COS-1 cells (ATCC CRL 1650) derived from kidney cells of an Africangreen monkey were cultured in DMEM supplemented with 10% (v/v) fetalcalf serum (Gibco), by a conventional procedure. To the cultured cells,the plasmids pSVL345 and pSVL324, and plasmid pSVL (Moch) not containingthe BSF2 expression unit, were separately transfected by a calciumphosphate method (Wigler et al. Cell, 14, 725-731, 1978). Namely, foreach palsmid, ×10⁶ cells/10 ml was put into a petri disk having adiameter of 100 mm, and cultured overnight, and 20 μg of plasmid in 1 mlof calcium phosphate solution (Chu, G. and Sharp, P. A., Gene, 13,197-202, 1981) was added to each culture. The next day, the medium wasexchanged and 10 ml of the medium was added, and after a furtherculturing for three days, a supernatant was recovered.

Detection of Soluble BSF2 Receptor in Supernatant

First, an enzyme immunoassay was carried out using an MT18 antibodydescribed in Example 11. Namely, the supernatant prepared as describedabove was diluted, and 200 μl of the diluted supernatant was put intoeach well of 96-well microtiter plate. After incubation at 4° C.overnight, the plate was washed with a washing solution. Next, 1% of aBSA solution was added to each well, and the plate was allowed to standat a room temperature for 90 minutes, to block the wells. Next, theplate was washed, and the MT18 antibody was added to the wells andincubation was carried out at a room temperature for 90 minutes. Againthe plate was washed, and an anti-mouse IgG26 rabbit antibody was addedto the wells, and incubation was carried out at a room temperature for60 minutes, then after washing the plate, an enzyme-labeled anti-rabbitIgG goat antibody was added to the wells, an incubation was carried outat a room temperature for 60 minutes. After again washing the plate,p-nitrophenyl phosphate as a substrate was added to the wells to carryout an enzyme reaction for 30 minutes, and after the reaction, theabsorbance (O.D. 405-600 nm) was measured by a microplate reader (Toso,Japan).

The result is set forth in FIG. 14. As seen from the FIG. 14,supernatants from COS-1 cells transfected with pSVL345 and pSVL324,respectively, contained a product which binds to the MT18 antibody, buta supernatant from COS-1 cells transfected with pSVL not containing theBSF2 receptor expression unit did not contain a product which binds tothe MT18 antibody.

Next, a soluble BSF2 receptor in the supernatants was detected by amethod using the MT18 antibody and ¹²⁵I-BSF2, by the same procedure asin Example 9. The result is set forth in FIG. 15. As seen from the FIG.15, in comparison to the supernatant from COS-1 cells transfected withpSVL, the supernatants from COS-1 cells transfected with pSVL345 andpSVL324, respectively, contained a product which binds to both the MT18antibody and ¹²⁵I-BSF2. Moreover, where cold BSF2 was added to thesupernatant, the count was dose-dependently decreased. This confirmsthat the product in the supernatant was a soluble BSF2 receptor (seeFIG. 16).

As another confirmation, the presence of a soluble BSF2 receptor in thesupernatant was confirmed by a method using the MT18 antibody, BSF2, andan anti-BSF2 rabbit antibody. Namely, 200 μl of 5 μg/ml MT18 antibodywag added to each well of a microtiter plate, and the plate wasincubated at 40° C. overnight. After washing the plate, the wells wereblocked with 1% of a BSA solution at a room temperature for 90 minutes,and after again washing the plate, a suitably diluted culturesupernatant was added to the well, and an incubation was carried out ata room temperature for 60 minutes. Then, after washing, a 100 ng/ml BSF2solution containing 10% FCS was added to the well, which was incubatedat a room temperature for 60 minutes. Again after washing, 500 ng/mlanti-BSF2 rabbit IgG antibody was added to the well, and incubation wascarried out at a room temperature for 60 minutes, and after anotherwashing, an enzyme-labeled anti-rabbit IgG goat IgG antibody was addedto the well and incubation was carried out at a room temperature for 60minutes. Subsequently, the plate was treated by the same procedure asdescribed above. The result is set forth in FIG. 17. In comparison witha supernatant from COS-1 cells transfected with pSVL, it was confirmedthat supernatants from COS-1 cells transfected with pSVL345 and pSVL324,respectively, contained a product which binds to both the MT18 antibodyand BSF2.

Finally, the supernatants were subjected to SDS-polyacrylamide gelelectrophoresis, the electrophoresis pattern was transblotted to anitrocellulose sheet, and the MT18 antibody was added to themicrocellulose sheet. Next, to the nitrocellulose sheet was added abiotinated anti-mouse IgG antibody followed by streptoavidin-alkalinephosphatase. Finally, NBT/BCIP as a substrate was added to thenitrocellulose sheet to develop the products. The result is set forth inFIG. 18. Supernatant from COS-1 cells transfected with pSVL324 exhibiteda band at 42 kD, and supernatant from COS-1 cells transfected withpSVL345 exhibited a band at 50 kD, revealing the presence of a solubleBSF2 receptor in the supernatants.

FIG. 19 represents the structures of proteins produced in Examples 8, 9,and 10. In this figure, BSF2R.236 is a protein produced by a plasmidpBSF2R.236, and corresponds to a native BSF2 receptor. ΔBSF2RI.1represents a protein produced by a plasmid pΔBSF2RI.1, ΔBSF2RII.5represents a protein produced by a plasmid pΔBSF2RII.5, SVL324represents a protein produced by a plasmid pSVL324, hβABSF2R representsa protein produced by a plasmid phβABSF2R and SVL345 represents aprotein produced by plasmid pSVL345. Since not only BSF2R.236, but alsoΔBSF2RII.5, DRN1, and hβABSF2R exhibit a BSFR receptor activity, it wasconfirmed that shortened proteins wherein a portion of the amino acidsequence near the N-terminal of the native BSF2 receptor protein hasbeen deleted, and shortened proteins wherein a portion of C-terminalincluding a membrane penetration region and an intracellular proteinregion of the native BSF2 receptor protein has been deleted, stillexhibit a BSF2 receptor activity.

Example 11 Production of Monoclonal Antibody to BSF2 Receptor

To prepare an immunogen for the production of a monoclonal antibody tothe BSF2 receptor, a mouse T cell line expressing human BSF2 receptor onthe surface was prepared as follows. The plasmid pBSF2R.236 described inExample 4 and the plasmid pSV2 neo were cotransfected to cells of amouse cell line CTLL-2 (ATCC TIB214), then subjected to a screeningprocedure using G-418, and eventually a cell line expressing about30,000/cell of BSF2 receptor was established, and designated as CTBC3.

The CTBC3 cells were cultured in RPMI 1640 by a conventional procedure,and the cultured cells were washed three times with PBS buffer. Thewashed cells were intraperitonealy injected to C57BL6 mouse in an amountof 1×10⁷ cells/mouse, once a week for a total of six times, to immunizethe mouse. Spleen cells from the immunized mouse were fused with amyeloma cell line P301 by a conventional procedure usingpoly-ethyleneglycol, and a desired hybridoma was selected as follows. Ahuman T cell line JURKAT (ATCC CRL8163), which is BSF2 receptornegative, was cotransfected with pBSF2R.236 and pSV2 neo, and thetransfected cells were screened. A cell line, which expresses100,000/cell of BSF2 receptor, was established and designated as NJBC8.One clone of hybridoma, which recognizes NJBC8 cells lyzed with NP40 anddoes not recognize JURKAT cells lyzed with NP40, was isolated anddesignated as MT18. An monoclonal antibody produced by the hybridomaMT18 is designated as an MT18 antibody. FIG. 20 shows that the MT18antibody specifically recognizes the BSF2 receptor. In this figure, Arepresents a graph of fluorescence intensity versus cell frequency whereJURKAT cells were stained by an MT18 antibody labeled withfluoresceinisocyanate, and B represents a similar result where NJBC8cells were similarly stained.

What is claimed is:
 1. An isolated DNA coding for a human B cellstimulating factor-2 receptor protein comprising amino acid 20 to aminoacid 468 in the following amino acid sequence (I): Met Leu Ala Val GlyCys Ala Leu Leu Ala Ala Leu Leu Ala Ala Pro Gly Ala Ala Leu Ala Pro ArgArg Cys Pro Ala Gln Glu Val Ala Arg Gly Val Leu Thr Ser Leu Pro Gly AspSer Val Thr Leu Thr Cys Pro Gly Val Glu Pro Glu Asp Asn Ala Thr Val HisTrp Val Leu Arg Lys Pro Ala Ala Gly Ser His Pro Ser Arg Trp Ala Gly MetGly Arg Arg Leu Leu Leu Arg Ser Val Gln Leu His Asp Ser Gly Asn Tyr SerCys Tyr Arg Ala Gly Arg Pro Ala Gly Thr Val His Leu Leu Val Asp Val ProPro Glu Glu Pro Gln Leu Ser Cys Phe Arg Lys Ser Pro Leu Ser Asn Val ValCys Glu Trp Gly Pro Arg Ser Thr Pro Ser Leu Thr Thr Lys Ala Val Leu LeuVal Arg Lys Phe Gln Asn Ser Pro Ala Glu Asp Phe Gln Glu Pro Cys Gln TyrSer Gln Glu Ser Gln Lys Phe Ser Cys Gln Leu Ala Val Pro Glu Gly Asp SerSer Phe Tyr Ile Val Ser Met Cys Val Ala Ser Ser Val Gly Ser Lys Phe SerLys Thr Gln Thr Phe Gln Gly Cys Gly Ile Leu Gln Pro Asp Pro Pro Ala AsnIle Thr Val Thr Ala Val Ala Arg Asn Pro Arg Trp Leu Ser Val Thr Trp GlnAsp Pro His Ser Trp Asn Ser Ser Phe Tyr Arg Leu Arg Phe Glu Leu Arg TyrArg Ala Glu Arg Ser Lys Thr Phe Thr Thr Trp Met Val Lys Asp Leu Gln HisHis Cys Val Ile His Asp Ala Trp Ser Gly Leu Arg His Val Val Gln Leu ArgAla Gln Glu Glu Phe Gly Gln Gly Glu Trp Ser Glu Trp Ser Pro Glu Ala MetGly Thr Pro Trp Thr Glu Ser Arg Ser Pro Pro Ala Glu Asn Glu Val Ser ThrPro Met Gln Ala Leu Thr Thr Asn Lys Asp Asp Asp Asn Ile Leu Phe Arg AspSer Ala Asn Ala Thr Ser Leu Pro Val Gln Asp Ser Ser Ser Val Pro Leu ProThr Phe Leu Val Ala Gly Gly Ser Leu Ala Phe Gly Thr Leu Leu Cys Ile AlaIle Val Leu Arg Phe Lys Lys Thr Trp Lys Leu Arg Ala Leu Lys Glu Gly LysThr Ser Met His Pro Pro Tyr Ser Leu Gly Gln Leu Val Pro Glu Arg Pro ArgPro Thr Pro Val Leu Val Pro Leu Ile Ser Pro Pro Val Ser Pro Ser Ser LeuGly Ser Asp Asn Thr Ser Ser His Asn Arg Pro Asp Ala Arg Asp Pro Arg SerPro Tyr Asp Ile Ser Asn Thr Asp Tyr Phe Phe Pro Arg, (C-terminal).


2. A DNA coding for a fusion protein comprising said DNA according toclaim
 1. 3. A DNA according to claim 2, wherein the DNA is operativelylinked to at least one nucleotide sequence to regulate the expression ofthe DNA.
 4. An expression vector comprising a DNA according to claim 3.5. A host cell transformed with an expression vector according to claim4.
 6. A process for production of a fusion protein comprising a human Bcell stimulating factor-2 protein comprising culturing host cellstransformed with an expression vector containing a DNA according toclaim 2, wherein the DNA is operatively linked to at least onenucleotide sequence to regulate the expression of the DNA, andrecovering the fusion protein.
 7. A DNA according to claim 1, whereinthe DNA is operatively linked to at least one nucleotide sequence toregulate the expression of the DNA.
 8. An expression vector comprising aDNA according to claim
 7. 9. A host cell transformed with an expressionvector according to claim
 8. 10. A process for production of a human Bcell stimulating factor-2 receptor protein comprising culturing hostcells transformed with an expression vector comprising the DNA accordingto claim 1, wherein the DNA is operatively linked to at least onenucleotide sequence to regulate the expression of the DNA, andrecovering the protein.
 11. An isolated DNA coding for a human B cellstimulating factor-2 receptor protein comprising amino acid 20 to aminoacid 27 and amino acid 110 to amino acid 468 in the following amino acidsequence (1): Met Leu Ala Val Gly Cys Ala Leu Leu Ala Ala Leu Leu AlaAla Pro Gly Ala Ala Leu Ala Pro Arg Arg Cys Pro Ala Gln Glu Val Ala ArgGly Val Leu Thr Ser Leu Pro Gly Asp Ser Val Thr Leu Thr Cys Pro Gly ValGlu Pro Glu Asp Asn Ala Thr Val His Trp Val Leu Arg Lys Pro Ala Ala GlySer His Pro Ser Arg Trp Ala Gly Met Gly Arg Arg Leu Leu Leu Arg Ser ValGln Leu His Asp Ser Gly Asn Tyr Ser Cys Tyr Arg Ala Gly Arg Pro Ala GlyThr Val His Leu Leu Val Asp Val Pro Pro Glu Glu Pro Gln Leu Ser Cys PheArg Lys Ser Pro Leu Ser Asn Val Val Cys Glu Trp Gly Pro Arg Ser Thr ProSer Leu Thr Thr Lys Ala Val Leu Leu Val Arg Lys Phe Gln Asn Ser Pro AlaGlu Asp Phe Gln Glu Pro Cys Gln Tyr Ser Gln Glu Ser Gln Lys Phe Ser CysGln Leu Ala Val Pro Glu Gly Asp Ser Ser Phe Tyr Ile Val Ser Met Cys ValAla Ser Ser Val Gly Ser Lys Phe Ser Lys Thr Gln Thr Phe Gln Gly Cys GlyIle Leu Gln Pro Asp Pro Pro Ala Asn Ile Thr Val Thr Ala Val Ala Arg AsnPro Arg Trp Leu Ser Val Thr Trp Gln Asp Pro His Ser Trp Asn Ser Ser PheTyr Arg Leu Arg Phe Glu Leu Arg Tyr Arg Ala Glu Arg Ser Lys Thr Phe ThrThr Trp Met Val Lys Asp Leu Gln His His Cys Val Ile His Asp Ala Trp SerGly Leu Arg His Val Val Gln Leu Arg Ala Gln Glu Glu Phe Gly Gln Gly GluTrp Ser Glu Trp Ser Pro Glu Ala Met Gly Thr Pro Trp Thr Glu Ser Arg SerPro Pro Ala Glu Asn Glu Val Ser Thr Pro Met Gln Ala Leu Thr Thr Asn LysAsp Asp Asp Asn Ile Leu Phe Arg Asp Ser Ala Asn Ala Thr Ser Leu Pro ValGln Asp Ser Ser Ser Val Pro Leu Pro Thr Phe Leu Val Ala Gly Gly Ser LeuAla Phe Gly Thr Leu Leu Cys Ile Ala Ile Val Leu Arg Phe Lys Lys Thr TrpLys Leu Arg Ala Leu Lys Glu Gly Lys Thr Ser Met His Pro Pro Tyr Ser LeuGly Gln Leu Val Pro Glu Arg Pro Arg Pro Thr Pro Val Leu Val Pro Leu IleSer Pro Pro Val Ser Pro Ser Ser Leu Gly Ser Asp Asn Thr Ser Ser His AsnArg Pro Asp Ala Arg Asp Pro Arg Ser Pro Tyr Asp Ile Ser Asn Thr Asp TyrPhe Phe Pro Arg, (C-terminal).


12. A DNA coding for a fusion protein comprising said DNA according toclaim
 11. 13. A DNA according to claim 12, wherein the DNA isoperatively linked to at least one nucleotide sequence to regulate theexpression of the DNA.
 14. An expression vector comprising a DNAaccording to claim
 13. 15. A host cell transformed with an expressionvector according to claim
 14. 16. A process for production of a fusionprotein comprising a human B cell stimulating factor-2 proteincomprising culturing host cells transformed with an expression vectorcontaining a DNA according to claim 12, wherein the DNA is operativelylinked to at least one nucleotide sequence to regulate the expression ofthe DNA, and recovering the fusion protein.
 17. A DNA according to claim11, wherein the DNA is operatively linked to at least one nucleotidesequence to regulate the expression of the DNA.
 18. An expression vectorcomprising a DNA according to claim
 17. 19. A host cell transformed withan expression vector according to claim
 18. 20. A process for productionof a human B cell stimulating factor-2 receptor protein comprisingculturing host cells transformed with an expression vector comprisingthe DNA according to claim 11, wherein the DNA is operatively linked toat least one nucleotide sequence to regulate the expression of the DNA,and recovering the protein.
 21. An isolated DNA coding for a human Bcell stimulating factor-2 receptor protein comprising amino acid 20 toamino acid 323 in the following amino acid sequence (I): Met Leu Ala ValGly Cys Ala Leu Leu Ala Ala Leu Leu Ala Ala Pro Gly Ala Ala Leu Ala ProArg Arg Cys Pro Ala Gln Glu Val Ala Arg Gly Val Leu Thr Ser Leu Pro GlyAsp Ser Val Thr Leu Thr Cys Pro Gly Val Glu Pro Glu Asp Asn Ala Thr ValHis Trp Val Leu Arg Lys Pro Ala Ala Gly Ser His Pro Ser Arg Trp Ala GlyMet Gly Arg Arg Leu Leu Leu Arg Ser Val Gln Leu His Asn Ser Gly Asn TyrSer Cys Tyr Arg Ala Gly Arg Pro Ala Gly Thr Val His Leu Leu Val Asp ValPro Pro Glu Glu Pro Gln Leu Ser Cys Phe Arg Lys Ser Pro Leu Ser Asn ValVal Cys Glu Trp Gly Pro Arg Ser Thr Pro Ser Leu Thr Thr Lys Ala Val LeuLeu Val Arg Lys Phe Gln Asn Ser Pro Ala Glu Asp Phe Gln Glu Pro Cys GlnTyr Ser Gln Glu Ser Gln Lys Phe Ser Cys Gln Leu Ala Val Pro Glu Gly AspSer Ser Phe Tyr Ile Val Ser Met Cys Val Ala Ser Ser Val Gly Ser Lys PheSer Lys Thr Gln Thr Phe Gln Gly Cys Gly Ile Leu Gln Pro Asp Pro Pro AlaAns Ile Thr Val Thr Ala Val Ala Arg Asn Pro Arg Trp Leu Ser Val Thr TrpGln Asp Pro His Ser Trp Asn Ser Ser Phe Tyr Arg Leu Arg Phe Glu Leu ArgTyr Arg Ala Glu Arg Ser Lys Thr Phe Thr Thr Trp Met Val Lys Asp Leu GlnHis His Cys Val Ile His Asp Ala Trp Ser Gly Leu Arg His Val Val Gln LeuArg Ala Gln Glu Glu Phe Gly Gln Gly Glu Trp Ser Glu Trp Ser Pro Glu AlaMet Gly Thr Pro Trp Thr Glu Ser Arg Ser Pro Pro Ala Glu Asn Glu Val SerThr Pro Met Glu Ala Leu Thr Thr Asn Lys Asp Asp Asp Asn Ile Leu Phe ArgAsp Ser Ala Asn Ala Thr Ser Leu Pro Val Gln Asp Ser Ser Ser Val Pro LeuPro Thr Phe Leu Val Ala Gly Gly Ser Leu Ala Phe Gly Thr Leu Leu Cys IleAla Ile Val Leu Arg Phe Lys Lys Thr Trp Lys Leu Arg Ala Leu Lys Glu GlyLys Thr Ser Met His Pro Pro Tyr Ser Leu Gly Gln Leu Val Pro Glu Arg ProArg Pro Thr Pro Val Leu Val Pro Leu Ile Ser Pro Pro Val Ser Pro Ser SerLeu Gly Ser Asp Asn Thr Ser Ser His Asn Arg Pro Asp Ala Arg Asp Pro ArgSer Pro Tyr Asp Ile Ser Asn Thr Asp Tyr Phe Phe Pro Arg, (C-terminal).


22. A DNA coding for a fusion protein comprising said DNA according toclaim
 21. 23. A DNA according to claim 22, wherein the DNA isoperatively linked to at least one nucleotide sequence to regulate theexpression of the DNA.
 24. An expression vector comprising a DNAaccording to claim
 23. 25. A host cell transformed with an expressionvector according to claim
 24. 26. A process for production of a fusionprotein comprising a human B cell stimulating factor-2 proteincomprising culturing host cells transformed with an expression vectorcontaining a DNA according to claim 22, wherein the DNA is operativelylinked to at least one nucleotide sequence to regulate the expression ofthe DNA, and recovering the fusion protein.
 27. A DNA according to claim21, wherein the DNA is operatively linked to at least one nucleotidesequence to regulate the expression of the DNA.
 28. An expression vectorcomprising a DNA according to claim
 27. 29. A host cell transformed withan expression vector according to claim
 28. 30. A process for productionof a human B cell stimulating factor-2 receptor protein comprisingculturing host cells transformed with an expression vector comprisingthe DNA according to claim 21, wherein the DNA is operatively linked toat least one nucleotide sequence to regulate the expression of the DNA,and recovering the protein.
 31. An isolated DNA coding for a human Bcell stimulating factor-2 receptor protein comprising amino acid 20 toamino acid 344, in the following amino acid sequence (I): Met Leu AlaVal Gly Cys Ala Leu Leu Ala Ala Leu Leu Ala Ala Pro Gly Ala Ala Leu AlaPro Arg Arg Cys Pro Ala Gln Glu Val Ala Arg Oly Val Leu Thr Ser Leu ProGly Asp Ser Val Thr Leu Thr Cys Pro Gly Val Glu Pro Glu Asp Asn Ala ThrVal His Trp Val Leu Arg Lys Pro Ala Ala Gly Ser His Pro Ser Arg Trp AlaOly Met Gly Arg Arg Leu Leu Leu Arg Ser Val Gln Leu His Asp Ser Gly AsnTyr Ser Cys Tyr Arg Ala Gly Arg Pro Ala Gly Tyr Val His Leu Leu Val AspVal Pro Pro Glu G1U Pro Gln Leu Ser Cys Phe Arg Lys Ser Pro Leu Ser AsnVal Val Cys Glu Trp Gly Pro Arg Ser Thr Pro Ser Leu Thr Thr Lys Ala ValLeu Leu Val Arg Lys Phe Gln Asn Ser Pro Ala Glu Asp Phe Gln Glu Pro CysGln Tyr Ser Gln Glu Ser Gln Lys Phe Ser Cys Gln Leu Ala Val Pro Glu GlyAsp Ser Ser Phe Tyr IIe Val Ser Met Cys Val Ala Ser Ser Val Gly Ser LysPhe Ser Lys Thr Gln Thr Phe Gln Gly Cys Gly Ile Leu Gln Pro Asp Pro ProAla Asn Ile Thr Val Thr Ala Val Ala Arg Asn Pro Arg Trp Leu Ser Val ThrTrp Gln Asp Pro His Ser Trp Asn Ser Ser Phe Tyr Arg Leu Arg Phe Glu LeuArg Tyr Arg Ala Glu Arg Ser Lys Thr Phe Thr Thr Trp Met Val Lys Asp LeuGln His His Cys Val Ile His Asp Ala Trp Ser Gly Leu Arg His Val Val GlnLeu Arg Ala Gln Glu Glu Phe Gly Gln Gly Glu Tup Ser Glu Trp Ser Pro GluAla Met Gly Thr Pro Trp Thr Glu Ser Arg Ser Pro Pro Ala Glu Asn Glu ValSer Thr Pro Met Gln Ala Leu Thr Thr Asn Lys Asp Asp Asp Asn Ile Leu PheArg Asp Ser Ala Asn Ala Thr Ser Leu Pro Val Gln Asp Ser Ser Ser Val ProLeu Pro Thr Phe Leu Val Ala Gly Gly Ser Leu Ala Phe Gly Thr Leu Leu CysIle Ala Ile Val Leu Arg Phe Lys Lys Thr Trp Lys Leu Arg Ala Leu Lys G1UGly Lys Thr Ser Met His Pro Pro Tyr Ser Leu Gly Gln Leu Val Pro Glu ArgPro Arg Pro Thr Pro Val Leu Val Pro Leu Ile Ser Pro Pro Val Ser Pro SerSer Leu Gly Ser Asp Asn Thr Ser Ser His Asn Arg Pro Asp Ala Arg Asp ProArg Ser Pro Tyr Asp Ile Ser Asn Thr Asp Tyr Phe Phe Pro Arg,(C-terminal).


32. A DNA coding for a fusion protein comprising said DNA according toclaim
 31. 33. A DNA according to claim 32, wherein the DNA isoperatively linked to at least one nucleotide sequence to regulate theexpression of the DNA.
 34. An expression vector comprising a DNAaccording to claim
 33. 35. A host cell transformed with an expressionvector according to claim
 34. protein comprising culturing host cellstransformed with an expression vector comprising the DNA according toclaim 1, wherein the DNA is operatively linked to at least onenucleotide sequence to regulate the expression of the DNA, andrecovering the protein.
 36. A process for production of a fusion proteincomprising a human B cell stimulating factor-2 protein comprisingculturing host cells transformed with an expression vector containing aDNA according to claim 32, wherein the DNA is operatively linked to atleast one nucleotide sequence to regulate the expression of the DNA, andrecovering the fusion protein.
 37. A DNA according to claim 31, whereinthe DNA is operatively linked to at least one nucleotide sequence toregulate the expression of the DNA.
 38. An expression vector comprisinga DNA according to claim
 37. 39. A host cell transformed with anexpression vector according to claim
 38. 40. A process for production ofa human B cell stimulating factor-2 receptor protein comprisingculturing host cells transformed with an expression vector comprisingthe DNA according to claim 31, wherein the DNA is operatively linked toat least one nucleotide sequence to regulate the expression of the DNA,and recovering the protein.